Vanadyl−Thiazolidinedione Combination Agents for Diabetes Therapy

A series of vanadium compounds, chelated by ligands containing a thiazolidinedione moiety as an additional insulin-enhancing component, were produced in this study to create potentially synergistic compounds. A set of four bifunctional ligand precursors were synthesized:  (±)-5-{4-[(5-hydroxy-4-oxo-...

Full description

Saved in:
Bibliographic Details
Published in:Bioconjugate chemistry 2003-01, Vol.14 (1), p.212-221
Main Authors: Storr, Tim, Mitchell, Devin, Buglyó, Péter, Thompson, Katherine H, Yuen, Violet G, McNeill, John H, Orvig, Chris
Format: Article
Language:English
Subjects:
Animals
Chelating Agents - chemical synthesis
Diabetes mellitus
Diabetes Mellitus, Experimental - drug therapy
Drug Synergism
Hypoglycemia
Hypoglycemic Agents - chemical synthesis
Hypoglycemic Agents - pharmacology
Insulin
Ligands
Q1
Rats
Structure-Activity Relationship
Thiazoles - chemistry
Thiazoles - pharmacology
Thiazoles - therapeutic use
Thiazolidinediones
Vanadates - chemistry
Vanadates - pharmacology
Vanadates - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A series of vanadium compounds, chelated by ligands containing a thiazolidinedione moiety as an additional insulin-enhancing component, were produced in this study to create potentially synergistic compounds. A set of four bifunctional ligand precursors were synthesized:  (±)-5-{4-[(5-hydroxy-4-oxo-4H-pyran-2-ylmethyl)amino]benzyl}thiazolidine-2,4-dione (HL1), (±)-5-{4-[(5-hydroxy-1-methyl-4-oxo-1,4-dihydro-pyridin-2-ylmethyl)amino]benzyl}thiazolidine-2,4-dione (HL2), 5-[4-(5-hydroxy-4-oxo-4H-pyran-2-ylmethoxy)benzylidene]thiazolidine-2,4-dione (HL3), and (±)-5-[4-(5-hydroxy-4-oxo-4H-pyran-2-ylmethoxy)benzyl]thiazolidine-2,4-dione (HL4), each containing a metal chelating portion as well as a thiazolidinedione moiety. From this set of ligand precursors, air-stable VO(L1)2, VO(L3)2, and VO(L4)2 were prepared. The four ligand precursors and three complexes were tested for insulin-enhancing potential in STZ-diabetic rats and compared to rosiglitazone and BMOV, respectively. Both the ligand precursors HL1 and HL3 showed enhanced activity compared with that of rosiglitazone. The complex VO(L3)2 showed the most efficacious hypoglycemic effects in this study; however, neither additive nor synergistic effects were observed using this acute animal model.
ISSN:1043-1802
1520-4812
DOI:10.1021/bc025606m